Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An emerging toolkit for targeted cancer therapies.

Literature DB >> 22301131

An emerging toolkit for targeted cancer therapies.

Gordon B Mills¹.

Abstract

Entities: Disease

Mesh：

Substances：
Biomarkers, Tumor

Year: 2012 PMID： 22301131 PMCID： PMC3266025 DOI： 10.1101/gr.136044.111

Source DB: PubMed Journal: Genome Res ISSN： 1088-9051 Impact factor: 9.043

× No keyword cloud information.

43 in total

Review 1. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.

Authors: Gregory L Verdine; Loren D Walensky
Journal: Clin Cancer Res Date: 2007-12-15 Impact factor: 12.531

2. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors: Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal: Cancer Cell Date: 2007-10 Impact factor: 31.743

3. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors: Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal: Nature Date: 2005-05-15 Impact factor: 49.962

Review 4. The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

Authors: Kenneth P Olive; David A Tuveson
Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531

5. Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors: I Bernard Weinstein
Journal: Science Date: 2002-07-05 Impact factor: 47.728

6. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.

Authors: Alfonso Quintás-Cardama; Alexander J Lazar; Scott E Woodman; Kevin Kim; Merrick Ross; Patrick Hwu
Journal: Nat Clin Pract Oncol Date: 2008-10-21

Review 7. Translation of the Philadelphia chromosome into therapy for CML.

Authors: Brian J Druker
Journal: Blood Date: 2008-12-15 Impact factor: 22.113

Review 8. Targeted therapy for cancer using PARP inhibitors.

Authors: Christopher J Lord; Alan Ashworth
Journal: Curr Opin Pharmacol Date: 2008-08 Impact factor: 5.547

9. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

Authors: Nikhil Wagle; Michael F Berger; Matthew J Davis; Brendan Blumenstiel; Matthew Defelice; Panisa Pochanard; Matthew Ducar; Paul Van Hummelen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Stacey B Gabriel; Levi A Garraway
Journal: Cancer Discov Date: 2011-11-07 Impact factor: 39.397

10. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors:
Journal: Nature Date: 2008-09-04 Impact factor: 49.962

6 in total

Review 1. [Mutational tumor profiles beyond organ and tissue specificity: implications for diagnostics and clinical study design].

Authors: F Klauschen
Journal: Pathologe Date: 2014-11 Impact factor: 1.011